Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-02

Study Completion Date

2028-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer

NCT00897416

Breast Cancer

COMPLETED

Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women

NCT00900367

Breast Cancer

ACTIVE_NOT_RECRUITING

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women

NCT06441474

Breast Cancer Female

RECRUITING PHASE2

Adherence to Intensive Surveillance for Hereditary Breast Cancer

NCT00582803

Breast Cancer

COMPLETED

Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer

NCT00276120

Invasive Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. Among women without a history of breast cancer: to compare women with moderate risk breast cancer gene mutations (Mutation Carrier Group) to women with a 20-40% empiric lifetime risk of breast cancer (Empiric Risk Group) in terms of how likely they are to undergo recommended breast MRI screening.

OUTLINE: This is an observational study.

Patients complete a questionnaire and have their medical records reviewed on study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational

Patients complete a questionnaire and have their medical records reviewed on study.

Non-Interventional Study

Intervention Type OTHER

Non-interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Interventional Study

Non-interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \* \>= 30 years

* =\< 75 years
* Women with either:

* Genetic test results showing moderately increased breast cancer risk due to a pathogenic/likely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR
* Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)
* Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago
* Women recommended to undergo annual breast MRI and/or annual mammogram beginning at the time of their genetic counseling risk assessment
* English or Spanish speaking patients

Exclusion Criteria

* \* History of breast cancer before genetic counseling at University of Southern California (USC)

* Any metastatic cancer diagnosis at time of genetic counseling risk assessment
* Deceased
* Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes